Early phase I/II trials with gemtuzumab ozogamicin (Mylotarg®) in acute myeloid leukemia

Pharmacology, Toxicology and Pharmaceutical Science

• Gemtuzumab Ozogamicin 100%
• Acute Myeloid Leukemia 60%
• Antibody Conjugate 40%
• Side Effect 20%
• DNA 20%
• Toxicity 20%
• Adverse Event 20%
• Prognosis 20%
• Hepatotoxicity 20%
• Antibody 20%
• Vein Occlusion 20%
• Calicheamicin 20%
• Clinical Trial 20%
• Apoptosis 20%
• Antibiotics 20%

INIS

• myeloid leukemia 60%
• patients 40%
• evaluation 20%
• data 20%
• clinical trials 20%
• in vitro 20%
• therapy 20%
• diseases 20%
• synthesis 20%
• dna 20%
• reviews 20%
• toxicity 20%
• antibiotics 20%
• antibodies 20%
• food and drug administration 20%
• apoptosis 20%
• side effects 20%
• blasts 20%